- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–29
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Bosentan
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • New York, New York
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo
- Drug
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 33 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Beraprost Sodium 314d Modified Release Tablets, Placebo
- Drug
- Lead sponsor
- Lung Biotechnology PBC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Sitaxsentan, Sitaxsentan and Sildenafil
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 12
- States / cities
- Fountain Valley, California • Gainesville, Florida • Weston, Florida + 9 more